PE anti-mouse IL-9 Antibody
- 产品名称：
- PE anti-mouse IL-9 Antibody
- 产品类别：
- 抗体
- 产品编号：
- 514103
- 产品应用：
- 514103
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Recombinant full length mouse IL-9
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
- Concentration
- 0.2 mg/ml
- Storage & Handling
- The IL-9 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
ICFC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
See the protocol for?Th9 polarization of mouse splenocytes.
- Application References
(PubMed link indicates BioLegend citation) -
- Angkasekwinai P, et. al. 2010. Nat. Immunol. 11:250. (ICFC) PubMed
- Chang HC, et al. 2010. Nat. Immunol. 11:527. (ICFC) PubMed
- Takami M, et al. 2012. J Immunol. 188:4369. PubMed
- Reynolds LA, et al. 2012. J. Immunol. 189:1113. PubMed
- Kuwahara M, et al. 2014. Nat Commun. 5:3555. PubMed
- Product Citations
-
- Katrin Schaper‐Gerhardt et al. 2018. British journal of pharmacology. 1111/bph. PubMed
- Schwartz DM et al. 2019. Immunity. 50(1):106-120 . PubMed
- Kuwahara M, et al. 2014. Nat Commun. 5:3555. PubMed
- Zhou Y, et al. 2011. J Immunol. 186:4415. PubMed
- Jiang Y, et al. 2019. J Immunother Cancer. 7:28. PubMed
- Mikami N, et al. 2013. J Immunol. 190:4046. PubMed
- Gomez-Rodriguez J, et al. 2016. Nat Commun. 7:10857. PubMed
- Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
- Kim B, et al. 2010. Proc Natl Acad Sci U S A. 107:8742. PubMed
- Prins J, et al. 2015. Biol Reprod. 93: 95. PubMed
- Tan C, et al. 2010. J Immunol. 185:6795. PubMed
- Zhao Y, et al. 2016. Nat Commun. 7:12368. PubMed
- Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
- Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
- Chen J, et al. 2021. Oncol Lett. 21:409. PubMed
- RRID
- AB_2126639 (BioLegend Cat. No. 514103) AB_2562527 (BioLegend Cat. No. 514104)
- Structure
- Cytokine; 30-40 kD (Mammalian)
- Bioactivity
- Potentiates production of IgG, IgM, and IgE by IL-4-induced B lymphocytes; regulates granzyme family proteases; enhances proliferation of bone marrow mast cells with IL-3; production of IL-6 by mast cells
- Cell Sources
- IL-2 activated TH2 lymphocytes
- Cell Targets
- T lymphocytes, erythroid precursors
- Receptors
- IL-9R
- Biology Area
- Immunology
- Molecular Family
- Cytokines/Chemokines
- Antigen References
-
1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Quesniaux V, et al. 1992. Research Immunology 143:385.
3. Renauld J, et al. 1993. Adv. Immunol. 54:79.
4. Yang Y, et al. 1992. Leuk. Lymphoma 8:441.
- Regulation
- Upregulated by IL-1 after TCR activation, TNF-α; downregulated by antibodies to IL-2
- Gene ID
- 16198 View all products for this Gene ID
- UniProt
- View information about IL-9 on UniProt.org
